(MENAFN- ProactiveInvestors - Australia) Antisense Therapeutics (ASX: ANP) has been placed in pre-open this morning following the ASX granting the company a trading halt, pending the release of details regarding the FDA approval of KYNAMRO.
KYNAMRO is a first-in-class apo-B synthesis inhibitor currently under regulatory review for patients with homozygous familial hypercholesterolaemia (HoFH) to further reduce LDL cholesterol (LDL-C) in patients already maintaining a stable regimen of maximally-tolerated lipid-lowering therapies, and who require additional significant lipid-lowering therapy.
It is intended to reduce LDL-C by preventing the formation of atherogenic lipoproteins, the particles that carry cholesterol through the bloodstream.
KYNAMRO acts by blocking the production of apolipoprotein B (apo B), the protein that provides the structural core for these atherogenic particles, including LDL and lipoprotein-a (Lp(a)).
The halt will last until the earlier of an announcement being made to the market, or the opening of trade on Friday 1st February.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.